Cargando…

Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model

Chemotherapy-induced adverse effects can reduce the relative dose intensity and quality of life. In this study, we investigated the potential benefit of supplementary anamorelin and 5-aminolevulinic acid (5-ALA) as preventive interventions against a gemcitabine and cisplatin (GC) combination chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyake, Makito, Hori, Shunta, Itami, Yoshitaka, Oda, Yuki, Owari, Takuya, Fujii, Tomomi, Ohnishi, Sayuri, Morizawa, Yosuke, Gotoh, Daisuke, Nakai, Yasushi, Anai, Satoshi, Torimoto, Kazumasa, Tanaka, Nobumichi, Fujimoto, Kiyohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409153/
https://www.ncbi.nlm.nih.gov/pubmed/32709007
http://dx.doi.org/10.3390/cancers12071942
_version_ 1783567999645515776
author Miyake, Makito
Hori, Shunta
Itami, Yoshitaka
Oda, Yuki
Owari, Takuya
Fujii, Tomomi
Ohnishi, Sayuri
Morizawa, Yosuke
Gotoh, Daisuke
Nakai, Yasushi
Anai, Satoshi
Torimoto, Kazumasa
Tanaka, Nobumichi
Fujimoto, Kiyohide
author_facet Miyake, Makito
Hori, Shunta
Itami, Yoshitaka
Oda, Yuki
Owari, Takuya
Fujii, Tomomi
Ohnishi, Sayuri
Morizawa, Yosuke
Gotoh, Daisuke
Nakai, Yasushi
Anai, Satoshi
Torimoto, Kazumasa
Tanaka, Nobumichi
Fujimoto, Kiyohide
author_sort Miyake, Makito
collection PubMed
description Chemotherapy-induced adverse effects can reduce the relative dose intensity and quality of life. In this study, we investigated the potential benefit of supplementary anamorelin and 5-aminolevulinic acid (5-ALA) as preventive interventions against a gemcitabine and cisplatin (GC) combination chemotherapy-induced adverse effects in a mouse model. Non-cancer-bearing C3H mice were randomly allocated as follows and treated for 2 weeks—(1) non-treated control, (2) oral anamorelin alone, (3) oral 5-ALA alone, (4) gemcitabine and cisplatin (GC) chemotherapy, (5) GC plus anamorelin, and (6) GC plus 5-ALA. GC chemotherapy significantly decreased body weight, food intake, skeletal muscle mass and induced severe gastric mucositis, which resulted in decreased ghrelin production and blood ghrelin level. The supplementation of oral anamorelin to GC chemotherapy successfully mitigated decrease of food intake during the treatment period and body weight loss at day 8. In addition, analysis of the resected muscles and stomach revealed that anamorelin suppressed chemotherapy-induced skeletal muscle atrophy by mediating the downregulation of forkhead box protein O-1 (FOXO1)/atrogin-1 signaling and gastric damage. Our findings suggest the preventive effect of anamorelin against GC combination chemotherapy, which was selected for patients with some types of advanced malignancies in clinical practice.
format Online
Article
Text
id pubmed-7409153
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74091532020-08-26 Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model Miyake, Makito Hori, Shunta Itami, Yoshitaka Oda, Yuki Owari, Takuya Fujii, Tomomi Ohnishi, Sayuri Morizawa, Yosuke Gotoh, Daisuke Nakai, Yasushi Anai, Satoshi Torimoto, Kazumasa Tanaka, Nobumichi Fujimoto, Kiyohide Cancers (Basel) Article Chemotherapy-induced adverse effects can reduce the relative dose intensity and quality of life. In this study, we investigated the potential benefit of supplementary anamorelin and 5-aminolevulinic acid (5-ALA) as preventive interventions against a gemcitabine and cisplatin (GC) combination chemotherapy-induced adverse effects in a mouse model. Non-cancer-bearing C3H mice were randomly allocated as follows and treated for 2 weeks—(1) non-treated control, (2) oral anamorelin alone, (3) oral 5-ALA alone, (4) gemcitabine and cisplatin (GC) chemotherapy, (5) GC plus anamorelin, and (6) GC plus 5-ALA. GC chemotherapy significantly decreased body weight, food intake, skeletal muscle mass and induced severe gastric mucositis, which resulted in decreased ghrelin production and blood ghrelin level. The supplementation of oral anamorelin to GC chemotherapy successfully mitigated decrease of food intake during the treatment period and body weight loss at day 8. In addition, analysis of the resected muscles and stomach revealed that anamorelin suppressed chemotherapy-induced skeletal muscle atrophy by mediating the downregulation of forkhead box protein O-1 (FOXO1)/atrogin-1 signaling and gastric damage. Our findings suggest the preventive effect of anamorelin against GC combination chemotherapy, which was selected for patients with some types of advanced malignancies in clinical practice. MDPI 2020-07-17 /pmc/articles/PMC7409153/ /pubmed/32709007 http://dx.doi.org/10.3390/cancers12071942 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Miyake, Makito
Hori, Shunta
Itami, Yoshitaka
Oda, Yuki
Owari, Takuya
Fujii, Tomomi
Ohnishi, Sayuri
Morizawa, Yosuke
Gotoh, Daisuke
Nakai, Yasushi
Anai, Satoshi
Torimoto, Kazumasa
Tanaka, Nobumichi
Fujimoto, Kiyohide
Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model
title Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model
title_full Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model
title_fullStr Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model
title_full_unstemmed Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model
title_short Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model
title_sort supplementary oral anamorelin mitigates anorexia and skeletal muscle atrophy induced by gemcitabine plus cisplatin systemic chemotherapy in a mouse model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409153/
https://www.ncbi.nlm.nih.gov/pubmed/32709007
http://dx.doi.org/10.3390/cancers12071942
work_keys_str_mv AT miyakemakito supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT horishunta supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT itamiyoshitaka supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT odayuki supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT owaritakuya supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT fujiitomomi supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT ohnishisayuri supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT morizawayosuke supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT gotohdaisuke supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT nakaiyasushi supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT anaisatoshi supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT torimotokazumasa supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT tanakanobumichi supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel
AT fujimotokiyohide supplementaryoralanamorelinmitigatesanorexiaandskeletalmuscleatrophyinducedbygemcitabinepluscisplatinsystemicchemotherapyinamousemodel